13 results about "Iron levels" patented technology

The present invention belongs to the technical field of biomedicine. Disclosed are stem-cell-derived apoptotic extracellular vesicles (ApoEVs) having an iron homeostasis regulatory effect and the use thereof in the preparation of a drug for treating iron deficiency anemia. ApoEVs are extracellular vesicles isolated from apoptotic cells derived from human periodontal ligament stem cells, and can effectively restore low intracellular iron levels induced by deferoxamine mesylate (DFOM), upregulate the expression of iron storage proteins and regulate the levels of iron export proteins, thereby improving cellular iron homeostasis. Moreover, the ApoEVs have good biocompatibility and safety, and provide a new strategy for the treatment of iron deficiency anemia.

The invention features methods of treating iron overload in a subject by administering BMP or hepcidin inhibitors, such as ALK2 inhibitors. The invention also features methods of decreasing iron levels in a subject by administering BMP or hepcidin inhibitors.

A method of testing the concentration of molybdate corrosion inhibitor in water of a central heating system is disclosed. The method comprises testing the iron concentration using an immersion test pad and testing the molybdate concentration using an immersion test pad. In the evaluation of the immersion test pad testing the molybdate concentration, the level of iron evaluated is taken into account. This results in more accurate and reliable results than achieved with known immersion tests.

The invention relates to novel compounds of the general formula (I-A) as defined in the application and pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and / or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders leading to increased iron levels or increased iron absorption, and / or iron overload.

Provided herein are systems and methods of assessing a concentration of iron in a body fluid sample, such as whole blood. Systems include a highly stable, fast reacting, and accurate sensing area of a sensor for contacting with a body fluid sample, wherein upon contact, the body fluid sample causes a color change to the sensor that correlates with the concentration of iron in the body fluid sample. The disclosed systems and methods generate one or more signal outputs of light intensity data, from which the concentration of iron in the body fluid sample is determined.

Disclosed are compositions and methods in the field of nutraceuticals, and in particular to nutraceuticals comprising at least one iron-sequestering glycoprotein and at least one chromium. These compositions find use in supporting formation of red blood cells and hemoglobin. Specifically, disclosed is a composition comprising the combination of apolactoferrin and chromium chloride trivalent to bind iron with the globin protein to regulate iron levels in mammals particularly humans.

Provided herein are systems and methods of assessing a concentration of iron in a body fluid sample, such as whole blood. Systems include a highly stable, fast reacting, and accurate sensing area of a sensor for contacting with a body fluid sample, wherein upon contact, the body fluid sample causes a color change to the sensor that correlates with the concentration of iron in the body fluid sample. The disclosed systems and methods generate one or more signal outputs of light intensity data, from which the concentration of iron in the body fluid sample is determined.

The invention relates to a pharmaceutical composition comprising iron (III) polymaltose complex and an active ingredient selected from calcium folinate pentahydrate, vitamin C or a combination of both, wherein the active ingredients are stored separately in a container consisting of a cylindrical bottle and a storage closure, wherein the iron (III) polymaltose is stored in the form of an oral solution in the bottle and the calcium folinate pentahydrate or vitamin C or a combination thereof are stored separately in a sealed manner in solid form in the storage closure. The container is properly configured to allow the two substances to be mixed just before use, forming a single-dose oral solution. The pharmaceutical composition helps to increase blood iron levels and treat anemia in pregnancy and lactation.

The present invention relates to a novel process for the preparation of compounds of formula (I) and pharmaceutically acceptable salts thereof, which are suitable for use as drugs for the prevention and / or treatment of diseases caused by hepcidin deficiency or iron metabolism disorders leading to increased iron levels or increased iron absorption, including iron overload, thalassemia, sickle cell disease and hemochromatosis.

The invention discloses application of ferroptosis and copper overload superimposed effect in endometrial cancer mitochondrial injury kit detection, and the kit verifies the detection effect of ferroptosis and copper overload dual effect in endometrial cancer proliferation inhibition by detecting the Iron level of an endometrial cancer treatment group and LPO, ROS and GSH content indexes. The ferroptosis and copper overload superimposed effect plays an important role in preparing the endometrial cancer cell mitochondrial injury effect detection kit, provides a theoretical basis for clinical diagnosis and treatment of endometrial cancer, and has important clinical significance and research value.

The present invention relates to novel compounds of general formula (I-A) as defined in the present application and pharmaceutical compositions comprising them and their use as medicaments, in particular as inhibitors of iron transporters, more particularly for the prevention and / or treatment of diseases caused by hepcidin deficiency or iron metabolism disorders leading to elevated iron levels, increased iron absorption and / or iron overload. # imgabs0 #

The present disclosure relates to a circular RNA molecule having an iron responsive element (IRE) comprising the sequence of SEQ ID NO: 1, SEQ ID NO:4, or a portion thereof sufficient to allow for binding to an iron responsive protein. Also disclosed are DNA constructs encoding the circular RNA molecule, host cells that include the circular RNA molecule, pharmaceutical compositions comprising the circular RNA molecule or DNA constructs encoding the circular RNA molecule, and methods of treating a disease or disorder mediated by iron overload.

The present invention relates to novel compounds of general formula (IA) as defined in the present application and pharmaceutical compositions comprising them and their use as medicaments, in particular for use as ferroportin inhibitors, more particularly for use in the prevention and / or treatment of diseases caused by a lack of hepcidin or disorders of iron metabolism leading to elevated iron levels or increased iron absorption and / or iron overload. JPEG2025535398000130.jpg36129